Document ID: chunk:federal_register_of_legislation:F2023L01745:schedule:1:p2
Version: federal_register_of_legislation:F2023L01745
Segment Type: schedule
Provision Reference: sch 1 (pt 2/42)
Character Range: 5550–9316

2  See Schedule 2

    [7]           Schedule 1, entry for Lumacaftor with ivacaftor
    substitute:
Lumacaftor with ivacaftor  Sachet containing granules, lumacaftor 75 mg and ivacaftor 94 mg    Oral  Orkambi  C14757 C14765     See Schedule 2  See Schedule 2
                           Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg  Oral  Orkambi  C14757 C14765     See Schedule 2  See Schedule 2
                           Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg  Oral  Orkambi  C14757 C14765     See Schedule 2  See Schedule 2
                           Tablet containing lumacaftor 100 mg with ivacaftor 125 mg           Oral  Orkambi  C14783 C14784     See Schedule 2  See Schedule 2
                           Tablet containing lumacaftor 200 mg with ivacaftor 125 mg           Oral  Orkambi  C14785 C14796     See Schedule 2  See Schedule 2

    [8]           Schedule 1, entry for Pomalidomide
    substitute:
Pomalidomide  Capsule 1 mg  Oral  Pomolide             C13746 C13755 C13757 C13768     See Schedule 2  See Schedule 2
              Capsule 2 mg  Oral  Pomolide             C13746 C13755 C13757 C13768     See Schedule 2  See Schedule 2
              Capsule 3 mg  Oral  Pomalidomide Sandoz  C13746 C13755 C13757 C13768     See Schedule 2  See Schedule 2
                                  Pomalyst             C13746 C13755 C13757 C13768     See Schedule 2  See Schedule 2
                                  Pomolide             C13746 C13755 C13757 C13768     See Schedule 2  See Schedule 2
              Capsule 4 mg  Oral  Pomalidomide Sandoz  C13746 C13755 C13757 C13768     See Schedule 2  See Schedule 2
                                  Pomalyst             C13746 C13755 C13757 C13768     See Schedule 2  See Schedule 2
                                  Pomolide             C13746 C13755 C13757 C13768     See Schedule 2  See Schedule 2

    [9]           Schedule 1, entry for Ravulizumab in each of the forms: Solution concentrate for I.V. infusion 300 mg in 3 mL; and Solution concentrate for I.V. infusion 1,100 mg in 11 mL
         insert in numerical order in the column headed "Circumstances": C14744 C14746 C14747 C14748 C14749 C14780 C14791 C14797
    [10]       Schedule 1, entry for Ustekinumab
         insert in numerical order in the column headed "Circumstances": C14758 C14787 C14801
    [11]       Schedule 2, entry for Eculizumab
    substitute:
Eculizumab  C14781                              Sufficient for treatment for 4 weeks  0
            C13857                              1                                     0
            C14750 C14792                       Sufficient for treatment for 4 weeks  4
            C14753 C14754 C14793 C14799 C14805  Sufficient for treatment for 4 weeks  5
            C13464 C13660 C13661 C13684 C13845  6                                     5
            C13458 C13459 C13560                8                                     0

    [12]       Schedule 2, entry for Lumacaftor with Ivacaftor
    substitute:
Lumacaftor with ivacaftor  C14757 C14765 C14783 C14784 C14785 C14796  1 pack  5

    [13]       Schedule 2, entry for Pomalidomide [Maximum Quantity: 1 pack (21 capsules); Maximum Repeats: 5]
omit from the column headed "Maximum Repeats": 5  substitute: 0
    [14]       Schedule 2, entry for Ravulizumab
    substitute:
Ravulizumab  C13459 C14477 C14565 C14586 C14744 C14780 C14791 C14797  1 dose  0
             C14476 C14530 C14531 C14746 C14747 C14748 C14749         1 dose  2

    [15]       Schedule 2, entry for Ustekinumab
         insert in numerical order in the column headed "Circumstances": C14758 C14787 C14801
    [16]       Schedule 3, entry for Eculizumab
       (a)           omit:
   C6626     Atypical